Anika Therapeutics (ANIK) The Sidoti Small-Cap Virtual Investor Conference summary

Strategic focus and business transformation

• Refocusing capital allocation on core hyaluronic acid (HA) visco injection and regenerative solutions products to maximize return on invested capital.

• Divestiture of non-core assets, including completed sale of Arthrosurface and planned sale of Parcus Medical, to streamline operations.

• Shift from reliance on OEM channel to building a direct commercial channel for greater revenue growth and agility.

• Transformation expected to accelerate profitability and improve cash flow due to lower capital intensity of new focus areas.

• No anticipated need for external capital in the next 2–3 years, supported by a strong balance sheet and cash flow from core products.

Product pipeline and market expansion

• Integrity, a tendon augmentation patch, launched in July with over 500 cases and 40% sequential growth, targeting a $220M U.S. market.

• Hyalofast, a single-stage cartilage regeneration product, filed first PMA module in 2024; U.S. launch expected in 2026 with rapid adoption anticipated.

• Cingal, a next-generation OA pain product, is sold in 40+ countries; U.S. FDA filing expected after toxicity and bioequivalence studies in 2025.

• International OA pain business (Orthovisc, Monovisc, Cingal) has grown 14% YTD, with 2+ years of 18%+ growth, and ongoing geographic expansion.

• Continued investment in regulatory filings and commercial teams to support global growth, especially in underpenetrated regions like Asia.

Financial performance and outlook

• 2024 revenue guidance is $117–$121M, flat to modestly down due to OEM channel pressures; commercial channel expected to grow 14–19%.

• Commercial channel is the primary long-term growth driver, with double-digit growth expected to accelerate post-2026 as new products launch.

• OEM channel remains profitable and cash-generative, supporting investments in commercial expansion.

• Share buyback program in place, to be completed by 2026.

• No debt and $60M in cash provide financial flexibility for ongoing investments.